The FDA Just Approved Four More Nicotine Pouches. A Courtroom Is About to Ask If That Was a Mistake.

Thirty. That’s how many nicotine pouch products now carry FDA authorization, after the agency cleared four new Helix Innovations “on!” flavors — Rich Berry, two Cappuccino strengths, Autumn Spice — on August 4. FDA authorization is not the same thing as an endorsement, and it is definitely not the same thing as a jury’s opinion, which is the distinction a Florida courtroom is about to test.

“Authorized” is a floor, not a verdict — and this December, a jury gets to decide whether the marketing built on top of that floor crossed a line the FDA never asked about.

The FDA’s “premarket tobacco product application” (PMTA) pathway asks a narrower question than most people assume: not “is this good for you,” but “is authorizing this product for sale less harmful, on net, than leaving the market to unregulated alternatives.” Pouches clear that bar more easily than vapes do right now, which is part of why the agency has kept approving them even while vaping products face tighter scrutiny — a nicotine pouch doesn’t require combustion or inhalation into lungs, and regulators have judged the harm-reduction math to favor authorization over prohibition for adult smokers switching products.

What the PMTA pathway doesn’t examine is how a product gets marketed once it’s authorized, and that’s exactly where Philip Morris International’s ZYN is now facing real legal exposure. A federal judge in Florida has let a deceptive-marketing claim against PMI proceed, with trial set for December 2026. Baltimore has filed a separate suit against PMI and Swedish Match, alleging the companies built youth-targeted marketing on top of a product line that’s technically authorized for adult use. Both cases are making the same underlying argument: a product can clear FDA’s safety-and-availability bar and still be marketed in a way that finds its way to teenagers who were never supposed to be the customer.

If you work with teenagers or young adults, the FDA authorization count isn’t the number that should change your screening questions. The lawsuits are describing exactly the population you already worry about — kids encountering a product through packaging and flavor names, not through a doctor’s recommendation for smoking cessation. Ask about pouches the same way you’d ask about vapes, not as an afterthought once the vape question is answered.

Thirty products cleared, one trial date set. The FDA answered its question. December is when someone answers the one the FDA didn’t ask.